Iranian
Biomedical Journal
Volume 30, Issue 3 And 2 (4-2026)
IBJ 2026, 30(3 And 2): 165-173 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagheri A M, Forootanfar H, Dehghannoudeh G, Raeisi Estabragh M A, M. Banat I, Sokhandan H, et al . Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6. IBJ 2026; 30 (3 and 2) :165-173
URL: http://ibj.pasteur.ac.ir/article-1-5241-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5241-en.html
Amir Mohammad Bagheri 
, Hamid Forootanfar , Gholamreza Dehghannoudeh , Mohammad Amin Raeisi Estabragh , Ibrahim M. Banat , Hosnieh Sokhandan , Hadiseh Shokouhi , Mandana Ohadi * , Parvaneh Mehrbod*
, Hamid Forootanfar , Gholamreza Dehghannoudeh , Mohammad Amin Raeisi Estabragh , Ibrahim M. Banat , Hosnieh Sokhandan , Hadiseh Shokouhi , Mandana Ohadi * , Parvaneh Mehrbod*
Abstract:
Background: Influenza A virus (IAV) is a global health concern, increasing the exploration of alternative therapeutics. Biosurfactants (BSs) are biodegradable, non-toxic biomolecules with favorable biological activities. Acinetobacter junii B6, known for utilizing crude oil as a carbon and energy source, produces BSs. This study evaluated the antiviral potential of the lipopeptide biosurfactant (LPB) against H1N1/A/PR8/34 infection.
Methods: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID50) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.
Results: The extracted LPB caused a 1 log2 reduction in pre- and post-exposure treatments, whereas amantadine and oseltamivir reduced viral titers by more than 1 log2. Cell protection was favorable in all combination treatments except for LPB co-treatment. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.
Conclusion: While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.
Methods: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID50) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.
Results: The extracted LPB caused a 1 log2 reduction in pre- and post-exposure treatments, whereas amantadine and oseltamivir reduced viral titers by more than 1 log2. Cell protection was favorable in all combination treatments except for LPB co-treatment. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.
Conclusion: While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.
Type of Study: Full Length/Original Article |
Subject:
Pharmaceutical Biotechnology
References
1. Carty M, Guy C, Bowie AG. Detection of viral infections by innate immunity. Biochem Pharmacol. 2021:183:114316. [DOI:10.1016/j.bcp.2020.114316]
2. Ohadi M, Forootanfar H, Dehghannoudeh N, Banat IM, Dehghannoudeh G. The role of surfactants and biosurfactants in the wound healing process: A review. J Wound Care. 2023;32(4):xxxix-xlvi. [DOI:10.12968/jowc.2023.32.Sup4a.xxxix]
3. Mondal S, Acharjee A, Saha B. Utilization of natural surfactants: An approach towards sustainable universe. Vietnam J Chem. 2022;60(1):1-14. [DOI:10.1002/vjch.202100137]
4. Miceli RT, Corr DT, Barroso M, Dogra N, Gross RA. Sophorolipids: Anti-cancer activities and mechanisms. Bioorg Med Chem. 2022:65:116787. [DOI:10.1016/j.bmc.2022.116787]
5. Ahmadi-Ashtiani HR, Baldisserotto A, Cesa E, Manfredini S, Sedghi Zadeh H, Ghafori Gorab M, et al. Microbial biosurfactants as key multifunctional ingredients for sustainable cosmetics. Cosmetics. 2020;7(2):46. [DOI:10.3390/cosmetics7020046]
6. Ceresa C, Fracchia L, Sansotera AC, De Rienzo MAD, Banat IM. Harnessing the potential of biosurfactants for biomedical and pharmaceutical applications. Pharmaceutics. 2023;15(8):2156. [DOI:10.3390/pharmaceutics15082156]
7. Adu SA, Twigg MS, Naughton PJ, Marchant R, Banat IM. Characterisation of cytotoxicity and immunomodulatory effects of glycolipid biosurfactants on human keratinocytes. Appl Microbiol Biotechnol. 2023;107(1):137-52. [DOI:10.1007/s00253-022-12302-5]
8. Dias MAM, Nitschke M. Bacterial-derived surfactants: An update on general aspects and forthcoming applications. Braz J Microbiol. 2023;54(1):103-23. [DOI:10.1007/s42770-023-00905-7]
9. De Andrade CJ, Coelho AL, Feuser PE, De Andrade LM, Carciofi BA, De Oliveira D. Mannosylerythritol lipids: Production, downstream processing, and potential applications. Curr Opin Biotechnol. 2022:77:102769. [DOI:10.1016/j.copbio.2022.102769]
10. Gupta S, Raghuwanshi N, Varshney R, Banat IM, Srivastava AK, Pruthi PA, et al. Accelerated in vivo wound healing evaluation of microbial glycolipid containing ointment as a transdermal substitute. Biomed Pharmacother. 2017:94:1186-96. [DOI:10.1016/j.biopha.2017.08.010]
11. Sharifi F, Sharifi I, Ohadi M, Mohamadi N, Salarkia E, Banat IM, et al. The potential role of lipopeptide biosurfactant generated by acinetobacter junii B6 on Leishmania tropica: The synergy of lipopeptide biosurfactant and Glucantime. Int J Pept Res Ther. 2023;29(4):57. [DOI:10.1007/s10989-023-10531-4]
12. Gharaei S, Ohadi M, Hassanshahian M, Porsheikhali S, Forootanfar H. Isolation, optimization, and structural characterization of glycolipid biosurfactant produced by marine Isisolate Shewanella algae B12 and evaluation of its antimicrobial and anti-biofilm activity. Appl Biochem Biotechnol. 2022;194(4):1755-74. [DOI:10.1007/s12010-021-03782-8]
13. Crovella S, De Freitas LC, Zupin L, Fontana F, Ruscio M, Pena EPN, et al. Surfactin bacterial antiviral lipopeptide blocks in vitro replication of SARS-CoV-2. Appl Microbiol. 2022;2(3):680-7. [DOI:10.3390/applmicrobiol2030052]
14. Daverey A, Dutta K, Joshi S, Daverey A. Sophorolipid: A glycolipid biosurfactant as a potential therapeutic agent against COVID-19. Bioengineered. 2021;12(2):9550-60. [DOI:10.1080/21655979.2021.1997261]
15. Hegazy GE, Abu-Serie MM, Abou-Elela GM, Ghozlan H, Sabry SA. Soliman, N.A., et al. Bioprocess development for biosurfactant production by Natrialba sp. M6 with effective direct virucidal and anti-replicative potential against HCV and HSV. Sci Rep. 2022;12(1):16577. [DOI:10.1038/s41598-022-20091-0]
16. Ohadi M, Dehghannoudeh G, Forootanfar H, Shakibaie M, Rajaee M. Investigation of the structural, physicochemical properties, and aggregation behavior of lipopeptide biosurfactant produced by Acinetobacter junii B6. Int J Biol Macromol. 2018;112:712-9. [DOI:10.1016/j.ijbiomac.2018.01.209]
17. Ohadi M, Forootanfar H, Dehghannoudeh G, Eslaminejad T, Ameri A, Shakibaie M, et al. Antimicrobial, anti-biofilm, and anti-proliferative activities of lipopeptide biosurfactant produced by Acinetobacter junii B6. Microb Pathog. 2020:138:103806. [DOI:10.1016/j.micpath.2019.103806]
18. Bejeshk MA, Rajizadeh MA, Yari A, Bagheri F, Najafipour H, Dehghannoudeh G, et al. Lipopeptide biosurfactant produced by Acinetobacter junii B6 attenuates lung inflammatory, oxidative, and histopathological alterations due to asthma in rats. Int J Pept Res Ther. 2024;3091:9. [DOI:10.1007/s10989-024-10586-x]
19. Ohadi M, Dehghannoudeh G, Shakibaie M, Banat IM, Pournamdari M, Forootanfar H. Isolation, characterization, and optimization of biosurfactant production by an oil-degrading Acinetobacter junii B6 isolated from an Iranian oil excavation site. Biocatal Agric Biotechnol. 2017;12:1-9. [DOI:10.1016/j.bcab.2017.08.007]
20. Ohadi M, Forootanfar H, Rahimi HR, Jafari E, Shakibaie M, Eslaminejad T, et al. Antioxidant potential and wound healing activity of biosurfactant produced by Acinetobacter junii B6. Curr Pharm Biotechnol. 2017;18(11):900-8. [DOI:10.2174/1389201018666171122121350]
21. Mehrbod P, Abdalla MA, Njoya EM, Ahmed AS, Fotouhi F, Farahmand B, et al. South African medicinal plant extracts active against influenza A virus. BMC Complement Altern Med. 2018;18(1):112. [DOI:10.1186/s12906-018-2184-y]
22. Khodsiani M, Kianmehr Z, Brycki B, Szulc A, Mehrbod P. Evaluation of the antiviral potential of gemini surfactants against influenza virus H1N1. Arch Microbiol. 2023;205(5):184. [DOI:10.1007/s00203-023-03478-z]
23. Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces. 2013;108:366-73. [DOI:10.1016/j.colsurfb.2013.02.043]
24. Sartori GJ, Prado LD, Rocha HVA. Efavirenz dissolution enhancement IV-antisolvent nanocrystallization by sonication, physical stability, and dissolution. AAPS PharmSciTech. 2017;18(3):3011-20. [DOI:10.1208/s12249-017-0781-6]
25. Shokouhi Targhi H, Mehrbod P, Fotouhi F, Amininasab M. In vitro anti-influenza assessment of anionic compounds ascorbate, acetate and citrate. Virol J. 2022;19(88):25. [DOI:10.1186/s12985-022-01823-0]
26. Chattopadhyay D, Chawla-Sarkar M, Chatterjee T, Dey RS, Bag P, Chakraborti S, et al. Recent advancements for the evaluation of anti-viral activities of natural products. N Biotechnol. 2009;25(5):347-68. [DOI:10.1016/j.nbt.2009.03.007]
27. Shigeta S, Mori S, Watanabe J, Soeda S, Takahashi K, Yamase T. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Chemother. 1997;41(7);1423-7. [DOI:10.1128/AAC.41.7.1423]
28. Mehrabani M, Esmaeili-Tarzi M, Forootanfar H, Nematollahi MH, Banat IM, Ohadi M, et al. Lipopeptide biosurfactant from Acinetobacter junii B6: A promising natural surfactant for promoting angiogenesis. Int J Pept Res Ther. 2021;27:1197-203. [DOI:10.1007/s10989-021-10160-9]
29. Borhanabadi MA, Estabragh MAR, Dehghannoudeh G, Banat IM, Ohadi M, Moshafi MH. Optimization of calcium alginate hydrogel bioencapsulation of Acinetobacter junii B6, a lipopeptide biosurfactant producer. Jundishapur J Nat Pharm Prod. 2023;18(2):134325. [DOI:10.5812/jjnpp-134325]
30. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: The epidemiology and management. Infect Drug Resist. 2017;10:121-34. [DOI:10.2147/IDR.S105473]
31. Hegazy GE, Abu-Seri MM, Soliman NA, Teleb M, Abdel-Fattah YR. Superior anti-pulmonary viral potential of Natrialba sp. M6-producing surfactin and C50 carotenoid pigment with unveiling its action modes. Virol J. 2023;20(1):249. [DOI:10.1186/s12985-023-02215-8]
32. Çelik PA, Manga EB, Çabuk A, Banat IM. Biosurfactants' potential role in combating COVID-19 and similar future microbial threats. Appl Sci. 2020;11(1):334. [DOI:10.3390/app11010334]
33. Ma R, Daniel Raja FS, Kavitha R, Arumugam V, Palanisamy S, Saikia K, et al. Production cost of traditional surfactants and biosurfactants: Multifunctional microbial biosurfactants. Springer. 2023:22:495-511. [DOI:10.1007/978-3-031-31230-4_22]
34. Bjerk TR, Severino P, Jain S, Marques C, Silva AM, Pashirova T, et al. Biosurfactants: Properties and applications in drug delivery, biotechnology and ecotoxicology. Bioengineering. 2021;8(8):115. [DOI:10.3390/bioengineering8080115]
35. Ohadi M, Shahravan A, Dehghannoudeh N, Eslaminejad T, Banat IM, Dehghannoudeh G. Potential use of microbial surfactant in microemulsion drug delivery system: A systematic review. Drug Des Devel Ther. 2020;14:541-50. [DOI:10.2147/DDDT.S232325]
36. Smith ML, Gandolfi S, Coshall PM, Rahman PK. Biosurfactants: A COVID-19 perspective. Front Microbiol. 2020:11:1341. [DOI:10.3389/fmicb.2020.01341]
37. Cermelli C, Cuoghi A, Scuri M, Bettu C, Neglia RG, Ardizzoni A, et al. In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid. Virol J. 2011:8:141. [DOI:10.1186/1743-422X-8-141]
38. Subramaniam MD, Venkatesan D, Iyer M, Subbarayan S, Govindasami V, Roy A, et al. Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19. Curr Opin Environ Sci Health. 2020;17:72-81. [DOI:10.1016/j.coesh.2020.09.002]
39. Sanches BCP, Rocha CA, Martin Bedoya JG, Da Silva VL, Da Silva PB, Fusco-Almeida AM, et al. Rhamnolipid-based liposomes as promising nano-carriers for enhancing the antibacterial activity of peptides derived from bacterial toxin-antitoxin systems. Int J Nanomedicine. 2021;16:925-39. [DOI:10.2147/IJN.S283400]
40. Chowdhury T, Baindara P, Mandal SM. LPD-12: A promising lipopeptide to control COVID-19. Int J Antimicrob Agents. 2021;57(1):106218. [DOI:10.1016/j.ijantimicag.2020.106218]
41. Sarangi MK, Padhi S, Patel LD, Rath G, Nanda SS, Yi DK. Theranostic efficiency of biosurfactants against COVID-19 and similar viruses-A review. J Drug Deliv Sci Technol. 2022;76:103764. [DOI:10.1016/j.jddst.2022.103764]
42. Paiva WKV, Oliveira LC, Silva MCS, Oliveira MLP, Maia J, Padilha C, et al. Exploiting the biological activities of a lipopeptide extract produced by Bacillus subtilis UFPEDA 438 in light of the SARS-CoV-2 pandemic. Biocatal Agric Biotechnol. 2024:58;103215. [DOI:10.1016/j.bcab.2024.103215]
43. Hoste Alexis CR, Smeralda W, Cugnet A, Brostaux Y, Deleu M, Garigliany M, et al. The structure of lipopeptides impacts their antiviral activity and mode of action against SARS-CoV-2 in vitro. Appl Environ Microbiol. 2024;90(11):e01036-24. [DOI:10.1128/aem.01036-24]
44. Khan MA, Ullah K, Rahman N, Mahmood A, Müllertz A, Mannan A, et al. Formulation, characterization and in-vitro evaluation of self-nanoemulsifying drug delivery system containing rhamnolipid biosurfactant. J Drug Deliv Sci Technol. 2022:75:103673. [DOI:10.1016/j.jddst.2022.103673]
45. Nunes JCF, Magalhães FF, Araújo MT, Almeida MR, Freire MG, Tavares AP. Expansion of targeted drug-delivery systems using microbially sources biosurfactant: Green sustainable process for chemical and environmental engineering and science. Elsevier. 2022:105-120. [DOI:10.1016/B978-0-323-85146-6.00034-6]
46. Jeon WJ, Lee HK, Na Y-G, Jung M, Han SC, Hwang JH, et al. Antiviral lipid nanocarrier loaded with remdesivir effective against SARS-CoV-2 in vitro model. Int J Nanomedicine. 2023;18:1561-75. [DOI:10.2147/IJN.S391462]
47. Lai C, Wang X, Yang P. Cytokines network and influenza virus infection. Clin Microbial. 2014;3(3):147.
48. Zhang J, Liu J, Yuan Y, Huang F, Ma R, Luo B, et al. Two waves of pro-inflammatory factors are released during the influenza A virus (IAV)-driven pulmonary immunopathogenesis. Plos Pathog. 2020;16(2):e1008334. [DOI:10.1371/journal.ppat.1008334]
49. To EE, Erlich JR, Liong F, Luong R, Liong S, Esaq F, et al. Mitochondrial reactive oxygen species contribute to pathological inflammation during influenza A virus infection in mice. Antioxid Redox Signal. 2020;32(13):929-42. [DOI:10.1089/ars.2019.7727]
50. Chen K-K. Minakuchi M, Wuputra K, Ku C-C, Pan J-B, Kuo K-K, et al. Redox control in the pathophysiology of influenza virus infection. BMC Microbiol. 2020;20:214. [DOI:10.1186/s12866-020-01890-9]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |